Search Results
Sep 09, 2025, 03:30 ET Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman
Sept. 9, 2025 /PRNewswire/ -- Pheon Therapeutics (Pheon), a clinical-stage leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of accomplished oncology expert
More news about: Pheon Therapeutics
Sep 08, 2025, 21:00 ET AI for Today, Not Tomorrow: SixSense and Raytek Accelerate Smart Manufacturing in Taiwan
2025 /PRNewswire/ -- SixSense, the Singapore-headquartered pioneer in AI-powered Automated Defect Classification (AI-ADC), today announced that it has been selected by Raytek, one of Taiwan's leading advanced packaging companies, to deploy
More news about: SixSense Pte Ltd
Sep 08, 2025, 08:00 ET IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
adenosyltransferase 2a (MAT2A) inhibitor, in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with late-line methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer (UC). MTAP-deletion is estimated to occur in approximately
More news about: IDEAYA Biosciences, Inc.
Sep 07, 2025, 12:00 ET IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
clinical trial of IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) antibody drug conjugate (ADC), in an oral presentation today at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. The presentation
More news about: IDEAYA Biosciences, Inc.
Sep 06, 2025, 10:15 ET Antibody Discovery Market worth US$3.54 billion by 2030 with 13.3% CAGR | MarketsandMarkets™
and GAN-driven design), and comprehensive antigen design, immunization (via Alloy's ATX-Gx transgenic mice), and downstream characterization (e.g., ADC design). Notably, it combines high-throughput proteomics (ScreenPep) and AI/ML with strong translational disease biology across oncology, neurology,
More news about: MarketsandMarkets
Sep 05, 2025, 09:21 ET Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC
today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical
More news about: HUADONG MEDICINE
Sep 05, 2025, 01:00 ET Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
patients may be eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca. In addition, this test is now the first
More news about: Roche Diagnostics
Sep 05, 2025, 01:00 ET Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
patients may be eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca. In addition, this test is now the first
More news about: Roche Diagnostics
Sep 04, 2025, 08:30 ET Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs, Upcoming Webinar Hosted by Xtalks
this webinar, attendees will hear the story of a real-world ADC case study: a humanized single-chain antibody linked to a bacterial toxin protein. The team selected a bridging anti-drug antibody (ADA) assay based on the MSD platform, with the ADC biotinylated and conjugated to Sulfo-TAG, and introduced
More news about: Xtalks
Sep 04, 2025, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for September 2025
September 8 - Multidomain Biologics: Bioanalytical Strategies and InsightsSeptember 11 - Advancing ADC Design Through Site-Specific Conjugation and Stable Linkers CELL AND GENE THERAPYSeptember 4 - High-Titer
More news about: Xtalks
Sep 04, 2025, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
molecule adenosyltransferase 2a (MAT2a) inhibitor, and Trodelvy® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with methylthioadenosine phosphorylase (MTAP)-deletion solid tumors. IDEAYA is conducting the trial pursuant to a clinical study collaboration
More news about: IDEAYA Biosciences, Inc.
Sep 02, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Sep 02, 2025, 08:00 ET Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside
More news about: Whitehawk Therapeutics, Inc.
Sep 02, 2025, 08:00 ET SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025
Safety & efficacy of iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC), in patients with EGFR mutated Non-Small Cell Lung Cancer (NSCLC), both as monotherapy and in combination with Osimertinib will be presented
More news about: SystImmune, Inc.
Sep 01, 2025, 02:48 ET University medical center in Germany expands use of Sectra's solution with AI service--accelerates adoption of AI for enhanced efficiency and patient care
https://news.cision.com/sectra/r/university-medical-center-in-germany-expands-use-of-sectra-s-solution-with-ai-service-accelerates-ad,c4225913 The following files are available for download:
More news about: Sectra
Aug 29, 2025, 12:25 ET Jacobio Pharma Announces 2025 Interim Results
partners, we significantly alleviated the pressure of R&D investment, enabling the Company to focus resources on advancing our pan-KRAS inhibitor and ADC pipeline. Looking forward, we remain committed to a transformative innovation strategy, working hand in hand with global partners to accelerate the
More news about: Jacobio Pharma
Aug 29, 2025, 10:15 ET Pharmaceutical Contract Manufacturing Market worth US$311.95 billion by 2030 with 8.2% CAGR | MarketsandMarkets™
billion by the end of the period. This is mainly due to the high demand for outsourcing services for GLP-1 manufacturing, the growing ADC outsourcing for commercialized products, and the development and patent expiry of blockbuster biologics, which are paving the way for key biosimilars.
More news about: MarketsandMarkets
Aug 28, 2025, 10:44 ET FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
efficiencies and further extend our cash runway." Sutro's pipeline includes STRO-006, an integrin beta-6 ADC expected to enter clinical development in 2026, and a dual-payload ADC platform with an IND filing anticipated in 2027. The oncology company pioneering site-specific antibody drug conjugates
More news about: USA News Group
Aug 28, 2025, 05:40 ET Asieris Pharmaceuticals Releases 2025 Semi-Annual Report with Sustained Commercial Momentum and Breakthrough Innovation Poised for Launch
March 2025. Data to date indicate favorable safety, tolerability, and pharmacokinetic profiles. Preclinical studies of APL-2501 (CLDN6/9 ADC) and research on its proprietary linker platform were selected for poster presentations at the 2025 American Association for Cancer Research (AACR) Annual
More news about: Asieris
Aug 27, 2025, 18:38 ET Keymed Biosciences (02162.HK) meldet starke Zwischenergebnisse für 2025 mit beschleunigter Kommerzialisierung und robuster F&E-Dynamik
allergische Rhinitis (SAR) hinaus, mit laufenden Phase-III-Studien bei pädiatrischer AD und Prurigo nodularis.CMG901/AZD0901 (Claudin 18.2 ADC): Im Jahr 2023 erhielt AstraZeneca AB (AZ) eine exklusive globale Lizenz für Forschung, Entwicklung, Zulassung, Herstellung
More news about: Keymed
Aug 27, 2025, 17:31 ET Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight
12.9 ZYNLONTA (loncastuximab tesirine-lpyl): ADC Therapeutics/SOBI 12.10
More news about: DelveInsight Business Research, LLP
Aug 27, 2025, 14:59 ET Keymed Biosciences (02162.HK) annonce de solides résultats intermédiaires pour 2025, avec une commercialisation accélérée et une dynamique de R&D robuste
des essais de phase III en cours dans le domaine de la DA pédiatrique et du prurigo nodulaire.CMG901/AZD0901 (Claudin 18.2 ADC) : En 2023, AstraZeneca AB (AZ) a obtenu une licence mondiale exclusive pour la recherche, le développement, l'enregistrement, la fabrication
More news about: Keymed
Aug 27, 2025, 10:15 ET Protein A Resin Market worth US$2.0 billion by 2030 with 6.5% CAGR | MarketsandMarkets™
Antibody Drug Conjugates (ADC) Market Get access to the latest updates on
More news about: MarketsandMarkets
Aug 27, 2025, 09:49 ET Keymed Biosciences (02162.HK) informa de sólidos resultados provisionales para 2025
y la rinitis alérgica estacional (RAE), con ensayos de fase III en curso en DA y prurigo nodular pediátricos.CMG901/AZD0901 (ADC Claudin 18.2): En 2023, AstraZeneca AB (AZ) obtuvo una licencia global exclusiva para la investigación, el desarrollo, el registro,
More news about: Keymed
Aug 27, 2025, 09:12 ET Fosun International Announces 2025 Interim Results: Steady Growth in Core Businesses with Accelerated Innovation and Globalization
globally competitive innovations;Innovative drug business ushered in a period of rapid growth. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) currently in global Phase II clinical trials, has demonstrated strong competitiveness and shows potential to become a broad-spectrum anti-cancer drug;Global
More news about: Fosun